Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine - LARVOL DELTA

The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera (ASH 2025) - "Assessing the efficacy of the recombinant adjuvanted herpes zoster vaccine Shingrix® in this population is crucial, as it is the currently recommended option for zoster prevention. Larger prospective trials are necessary to confirm these findings and refine vaccination strategies in this vulnerable population. This work was supported by the Strategic Action in Health 2024 of the Instituto de Salud Carlos III (Spain) (PI24/00861)"

Clinical • IO biomarker • Herpes Zoster • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Varicella Zoster • CD4 • CD8 • GZMB • IFNG • IL2

Uptake of Shingrix vaccine in its first year on the National Immunisation Program: an analysis of Australian Immunisation Register data. (PubMed, Public Health Res Pract) - "N/A."

Journal

Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease. (PubMed, Hum Vaccin Immunother) - "In adults aged ≥50 with IBD, 2 doses of RZV effectively prevented HZ without increasing flare risk. These findings support current vaccination recommendations to prevent HZ in adults ≥50 years, including individuals with immunodeficiency or immunosuppression."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States. (PubMed, Vaccine) - "The clinical and economic value of RZV appears to be similar or superior to the other analyzed preventive services recommended for people aged ≥50 years in the United States, but, despite this, utilization is more limited."

Journal • Real-world evidence • Review • Colorectal Cancer • Hepatitis B • Herpes Zoster • Infectious Disease • Influenza • Oncology • Pertussis • Pneumococcal Infections • Respiratory Diseases • Solid Tumor • Tetanus • Varicella Zoster

RZVRheum: Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (clinicaltrials.gov) - P4 | N=2005 | Active, not recruiting | Sponsor: University of Sao Paulo General Hospital | Trial completion date: Dec 2027 ➔ Jun 2032

Trial completion date • Ankylosing Spondylitis • Dermatomyositis • Herpes Zoster • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Lupus • Myositis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Spondylarthritis • Systemic Lupus Erythematosus • Systemic Sclerosis • Varicella Zoster • Vasculitis

Disparities in Recombinant Zoster Vaccine Coverage in the United States. (PubMed, Popul Health Manag) - "In conclusion, only 1-in-7 non-institutionalized Americans aged ≥50 years reported RZV coverage by 2020, with significant disparities among subgroups defined by race and ethnicity, age, and levels of educational attainment, income, and insurance. These results highlight an opportunity to improve herpes zoster protection through increased vaccination, pursued in a more equitable manner."

Journal • Herpes Zoster • Infectious Disease • Influenza • Respiratory Diseases • Varicella Zoster

Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions (clinicaltrials.gov) - P=N/A | N=2844 | Active, not recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Apr 2029 ➔ Mar 2028

Enrollment closed • Trial completion date • Herpes Zoster • Psoriatic Arthritis • Varicella Zoster

Enhancing Herpes Zoster Vaccination Rates Among Oncology Outpatients: Impact of an In-House Vaccination Initiative. (PubMed, Cancers (Basel)) - "The recombinant zoster vaccine (RZV, Shingrix®) provides strong and durable protection against HZ and its complications...The approach highlights the key role of oncology teams in leading preventive interventions for immunocompromised patients. By integrating vaccination into routine cancer care, institutions can overcome traditional organizational barriers and align with current ASCO and ESMO recommendations for comprehensive patient protection."

Journal • Herpes Zoster • Oncology • Varicella Zoster

Low influenza, pneumococcal and herpes zoster vaccination coverage in Australian patients commencing a biologic or targeted synthetic disease modifying anti-rheumatic drug for inflammatory arthritis: a nationwide cross-sectional data linkage study. (PubMed, Rheumatol Int) - "Only 9.7% (n = 1500/15,460) received a pneumococcal vaccine and 2.4% (n = 367/15,460) received HZ vaccination (Zostavax or Shingrix) within 6 months of b/tsDMARD commencement. Vaccination rates in patients initiating a b/tsDMARD for the treatment of inflammatory arthritis in Australia should be improved. This may also apply to patients with IA in other countries."

Journal • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

PISSARRO: A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults (clinicaltrials.gov) - P3 | N=526 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • Herpes Zoster • Respiratory Diseases • Respiratory Syncytial Virus Infections • Varicella Zoster

Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma (ASH 2024) - "The recombinant adjuvanted herpes zoster vaccine (Shingrix®; HZ/su, GlaxoSmithKline Biologicals SA) has been approved for immunocompetent and immunocompromised patients, but data on its efficacy in patients with CLL and MM are scarce...Actively treated CLL patients have lower antibody titles but both CLL and MM patients increase their title even when actively treated. AEs were mostly local or low-grade systematic ones."

Clinical • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Immune Thrombocytopenic Purpura • Infectious Disease • Leukemia • Multiple Myeloma • Oncology • Thrombocytopenia • Thrombocytopenic Purpura • Varicella Zoster

Lichen planus following recombinant zoster vaccine. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatology • Dermatopathology • Herpes Zoster • Infectious Disease • Lichen Planus • Varicella Zoster

Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom (ISPOR-EU 2025) - "Vaccination with RZV could significantly reduce the HZ-related burden in adults aged 18-49 years living with an IC condition in the UK."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Herpes Zoster • Human Immunodeficiency Virus • Infectious Disease • Neuralgia • Solid Organ Transplantation • Solid Tumor • Varicella Zoster

Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and France: Lessons for Poland (ISPOR-EU 2025) - "Cost-effectiveness plays a central role in determining eligibility and funding, particularly for newer vaccines such as Shingrix and RSV... Poland can enhance its adult vaccination program by adopting a hybrid model: centralized coordination (UK), comprehensive vaccine access (US), and full reimbursement for high-risk groups (France). Incorporating HTA frameworks and cost-effectiveness analysis into national vaccine policy could improve resource allocation and support the adoption of newer vaccines. These strategies would strengthen public health infrastructure, improve vaccine uptake, and ensure more efficient use of healthcare resources."

Clinical • Herpes Zoster • Infectious Disease • Influenza • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Varicella Zoster

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over (clinicaltrials.gov) - P1/2 | N=764 | Recruiting | Sponsor: Dynavax Technologies Corporation | N=440 ➔ 764 | Trial completion date: Sep 2026 ➔ Nov 2031 | Trial primary completion date: Sep 2026 ➔ Nov 2027

Enrollment change • Trial completion date • Trial primary completion date • Herpes Zoster • Infectious Disease • Varicella Zoster

Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases (ACR Convergence 2025) - "This study aimed to evaluate B-cell and T-cell immune responses to the recombinant HZ vaccine in IMID patients treated with JAK inhibitors (JAK-i), anti-TNF therapies, or methotrexate (MTX), and to identify factors associated with reduced vaccine-induced immunity. This study investigated both humoral and cellular immune responses following a two-dose regimen of the recombinant inactivated vaccine in 131 patients with IMIDs treated with JAK inhibitors, anti-TNF therapy, or MTX...Immunogenicity was negatively associated with cumulative MTX and glucocorticoid use, prior DMARDs, baricitinib and tofacitinib treatment, and longer JAK-i exposure... IMID patients treated with JAK inhibitors exhibit significantly reduced humoral and cellular immune responses to the HZ recombinant vaccine, suggesting lower protection against VZV reactivation. While some reduction was seen in the anti-TNF/MTX group, their immune responses remained relatively preserved. The findings underscore the..."

Herpes Zoster • Infectious Disease • Inflammation • Neuralgia • Varicella Zoster • CD4 • CD8

Herpes zoster frequency and adjuvanted recombinant zoster vaccination after allogeneic hematopoietic cell transplantation. (PubMed, Transplant Cell Ther) - "Overall, the receipt of aRZV did not seem to influence the frequency of HZ in patients post alloHCT, however, there may be disease severity modification and benefit if receiving beyond 12 months post HCT. We provide preliminary findings that would benefit from further evaluation in a prospective, randomized trial."

Journal • Herpes Zoster • Transplantation • Varicella Zoster

Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren's Disease Patients: Results From a Double-Blinded Placebo-Controlled Study (ACR Convergence 2025) - P4 | "Despite this vulnerability, data on safety and immunogenicity of the recombinant HZ vaccine (RZV, Shingrix®) in these patients remain limited... In this randomized, double-blind, placebo-controlled trial, 67 adults immunosuppressed SjD patients (excluding rituximab) were enrolled, alongside 201 non-immunosuppressed control individuals (CG)...Geometric Mean Titer (GMT) and Factor Increase (FI-GMT) were calculated. Vaccine (P1) and placebo (P2) groups were comparable in terms of age (p=0.5), sex (p=1.0), prednisone use (p=0.3) and dosage (0.6), as well as treatment with hydroxychloroquine (p=0.7), methotrexate (p=0.5), leflunomide (p=0.4), azathioprine (p=0.5), and mycophenolate mofetil (p=0.8)... RZV demonstrated an excellent safety profile in immunosuppressed SjD patients, without triggering significant disease flares. Although the vaccine induced a high rate of humoral response, the magnitude of the response was significantly lower compared to healthy..."

Clinical • Herpes Zoster • Immunology • Infectious Disease • Novel Coronavirus Disease • Rheumatology • Sjogren's Syndrome • Varicella Zoster

Accessing robust vaccine coformulation stability by single adjuvant detection on a microelectrode. (PubMed, Proc Natl Acad Sci U S A) - "We then present a time-trial comparison of data from current commercial SHINGRIX™ vaccines using dynamic light scattering and stochastic electrochemistry, analyzing the AS01B adjuvant alone and the AS01B adjuvant combined with the glycoprotein E (gE protein). While our method elucidates important properties at the single adjuvant level, our results paint a quantitative kinetic picture of coformulation stability that is currently not achievable by dynamic light scattering."

Journal

Design and Initial Results from a Cluster Randomized Trial of a Provider-Facing Immunization Dashboard to Improve Shingrix Vaccination in the Veterans Health Administration (ACR Convergence 2025) - "We designed an innovative wait-list randomized control trial of a provider-facing immunization dashboard to improve Shingrix vaccination. After 4 months of implementation, we observed no significant difference in Shingrix vaccination rates between early-access and control sites. This may reflect the typical 3–4 month interval between rheumatology visits."

Clinical • Herpes Zoster • Rheumatology • Varicella Zoster

Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination (ACR Convergence 2025) - P4 | "Although the adjuvanted recombinant zoster vaccine (RZV, Shingrix®) has shown high efficacy and a favorable safety profile in immunocompetent individuals, its performance in PsA and axSpA patients under immunosuppressive treatment has not been evaluated and may hamper vaccination recommendations for these patients... In this first prospective controlled study, RZV demonstrated favorable safety and high rates of immunogenicity in PsA and axSpA patients under immunosuppressive treatment. However, the lower frequency of seroconversion and reduced antibody titers compared to CG raise concerns about vaccine-induced protection. These findings support the use of RZV in high-risk patients and highlights the need for long-term monitoring of vaccine efficacy."

Clinical • Ankylosing Spondylitis • Herpes Zoster • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Varicella Zoster

Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine (ACR Convergence 2025) - P4 | "A trend toward reduced response with mycophenolate mofetil (MMF) was observed (30.8% vs. 57.1%, p=0.069) but not confirmed in multivariate analysis... In immunosuppressed IIM patients, RZV showed good short-term immunogenicity and safety, with no disease worsening. However, reduced post-vaccination antibody titers suggest a potential risk for diminished long-term protection, highlighting the need for continued monitoring. (ClinicalTrials NCT05879419)."

Clinical • P4 data • Dermatomyositis • Herpes Zoster • Immunology • Infectious Disease • Myositis • Novel Coronavirus Disease • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Varicella Zoster

First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes (ACR Convergence 2025) - P4 | "Although the recombinant zoster vaccine (RZV/Shingrix®) is approved for immunocompromised individuals, its immunogenicity, safety, and impact on disease activity (DA) have not been specifically evaluated in SSc patients... RZV is safe and highly immunogenic in immunosuppressed SSc patients, without affecting DA as measured by validated scores. However, lower antibody titers raise concerns about long-term protection, underscoring the need for ongoing monitoring in this population (ClinicalTrials NCT05879419)."

Clinical • Chronic Kidney Disease • Dermatology • Herpes Zoster • Immunology • Movement Disorders • Nephrology • Pulmonary Disease • Renal Disease • Scleroderma • Systemic Sclerosis • Varicella Zoster

Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration (ACR Convergence 2025) - "The use of a safety dashboard, combined with targeted outreach to primary care providers was associated with a steady increase in the administration of Shingrix among Veterans on DMARDs. We plan to expand the use of these dashboards to promote other recommended immunizations within this population. Prompt implementation of EHR-based dashboards can boost quality improvement efforts by delivering key metrics and actionable insights directly to clinicians."

Clinical • Hematological Disorders • Herpes Zoster • Infectious Disease • Rheumatology • Varicella Zoster

GSK plc…announced Tuesday that its Shingrix vaccine has received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for a new prefilled syringe presentation. (Investing.com) - "European Commission approval is expected in December 2025, GSK said in a statement."

CHMP • EMA approval • Infectious Disease